Overcoming Treatment Resistance
搜索文档
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Prnewswire· 2025-10-13 16:10
ATNM-400 Presentation Information Title: ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, demonstrates potent anti-tumor activity and overcomes osimertinib resistance in lung cancer models Session: Poster Session C Session Date and Time: Saturday, October 25, 2025, 12:30 – 4:00 PM E.T. The ATNM-400 abstract will be available for viewing online on October 22, 2025 at 12:00 PM E.T. through a freely available supplement in the AACR journal Molecular Cancer Therapeutics. , /PRNewswire/ -- Act ...
